放宽中高端医疗市场准入；脑机接口迎行业标准

Policy Developments - Nine departments, including the Ministry of Commerce, have announced measures to relax market access in high-end medical and leisure vacation sectors, aiming to attract more foreign and private investment and increase the supply of quality services [1] Industry Standards - The National Medical Products Administration has officially released the industry standard for medical devices using brain-computer interface technology, marking China's first standard in this field, which will take effect on January 1, 2026 [2] Drug and Device Approvals - Heng Rui Medicine announced that its subsidiaries received clinical trial approval for multiple products, including SHR-1826, an antibody-drug conjugate targeting c-MET, and two monoclonal antibodies [3] - New Industry received a medical device registration certificate for a cardiac fatty acid-binding protein assay kit, which aids in the diagnosis of acute myocardial infarction [4] - The National Medical Products Administration approved 263 medical device products in August 2025, including 208 domestic Class III devices and 31 imported Class III devices [8] Capital Market Activities - Yaoshi Technology announced that the last day for converting Yaoshi convertible bonds is September 17, after which unconverted bonds will be forcibly redeemed at a price of 100.62 yuan per bond [5] - Meiyang Innovation Technology completed a Pre-A+ round financing of several hundred million yuan, with funds aimed at accelerating clinical registration and technology iteration [6] Major Industry Events - Jitai Technology launched the world's first AI nano-delivery platform, NanoForge, which includes three core solutions for RNA delivery and small molecule formulation design [9] - Haizheng Pharmaceutical signed a strategic cooperation agreement with Shenzhen Aixin Dawei, involving the exclusive licensing of a novel small molecule prodrug, with total payments not exceeding 240 million yuan [10] Market Reactions - A stock of a Hong Kong innovative drug company experienced extreme volatility, with a peak increase of 115.58% followed by a drop of over 70%, resulting in a market value loss exceeding 200 billion HKD [11]